Biomedical Engineering Reference
In-Depth Information
Garattini S, Chalmers I (2009) Patients and the public deserve big changes in evaluation of drugs.
Br Med J 338(April):804-807
Garnier J-P (2008) Rebuilding the R&D engine in big pharma. Harvard Business Review, May,
pp 68-76
Gilbert J, Henske P, Singh A (2003) Rebuilding big pharma's business model. In Vivo
21(10):1-10
Gilbody S, Wilson P, Watt I (2005) Benefits and harms of direct to consumer advertising: a system-
atic review. Qual Saf Health Care 14:246-250
Government Accountability Office (2006) Prescription drugs: improvements needed in FDA's
oversight of direct-to-consumer advertising. G.A.O., Washington, DC.
http://prescription-
10 Feb 2011
Greene JA, Choudry NK, Kilabuk E, Shrank WH (2010) Online social networking by patients with
diabetes: a qualitative evaluation of communication with facebook. J Gen Intern Med
26(3):287-292
Grundy SM, Cleeman JI, Merz CNB, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC,
Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the national cholesterol
education program adult treatment panel III guidelines. Circulation 44(3):720-732
Herxheimer A (2003) Relationships between the pharmaceutical industry and patients' organisa-
tions. Br Med J 326(31):1208-1210
Hilsenrath P (2011) Health expenditure efficiency: implications for pharmaceutical marketing. Int
J Pharm Healthc Mark 5(2):118-134
Hollon MF (1999) Direct-to-consumer marketing of prescription drugs creating consumer demand.
J Am Med Assoc 281(4):382-384
Holmer AF (1999) Direct-to-consumer prescription drug advertising builds bridges between
patients and physicians. J Am Med Assoc 281(4):380-382
Inglehart R, Baker WE (2000) Modernization, cultural change and the persistence of traditional
values. Am Sociol Rev 65(1):19-51
Iizuka T, Jin GZ (2005) The effect of prescription drug advertising on doctor visits. J Econ Manag
Strat 14(3):701-727
't Jong GW, Stricker BHC, Sturkenboom MCJM (2004) Marketing in the lay media and prescrip-
tions of terbinafine in primary care: Dutch cohort study. Br Med J 328:321
Kahn B, Luce MF (2003) Understanding high-stakes consumer decisions: mammography adher-
ence following false-alarm test results. Mark Sci 22(3):393-410
Karlsson N, Loewenstein G, McCafferty J (2004) The economics of meaning. Nord J Polit Econ
30(1):61-75
Kim HS, Sherman DK (2007) “Express yourself”: culture and the effect of self-expression on
choice. J Pers Soc Psychol 92(1):1-11
Kolsarici C, Vakratsas D (2010) Category versus brand-level advertising messages in a highly
regulated environment. J Mark Res 47(6):1078-1089
Krahn M, Naglie G (2008) The next step in guideline development: incorporating patient prefer-
ences. J Am Med Assoc 300(4):436-438
Kremer STM, Bijmolt THA, Leeflang PSH, Wieringa JE (2008) Generalizations on pharmaceuti-
cal marketing effectiveness. Int J Res Mark 25(4):234-246
Kumar V, Aksoy L, Donkers B, Venkatesan R, Wiesel T, Tillmanns S (2010) Undervalued or over-
valued customers: capturing total customer engagement value. J Serv Res 13(3):297-310
Lee KL, Fader P, Hardie B (2007) How to project patient persistency. Foresight 8(Fall):31-35
Luce MF, Kahn BE (1999) Avoidance or vigilance? The psychology of false-positive test results.
J Consum Res 26(3):242-259
Manchanda P, Wittink DR, Ching A, Cleanthous P, Ding M, Dong XJ, Leeflang PS, Misra S, Mizik
N, Narayanan S, Steenburgh T, Wieringa JE, Wosinska M, Xie Y (2005) Understanding firm,
physician and consumer choice behavior in the pharmaceutical industry. Mark Lett
16(3/4):293-308
Search WWH ::
Custom Search